RPRX - Royalty Pharma plc
NEXT EARNINGS:
May 7, 2026
EPS Est: $1.23
|
Rev Est: $934.9M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$49.25
DETAILS
HIGH:
$61.00
LOW:
$42.00
MEDIAN:
$47.00
CONSENSUS:
$49.25
UPSIDE:
8.48%
Market Cap:
19.45B
Volume:
2,518,133
Avg Volume:
4,061,635
52 Week Range:
29.66-46.14
Sector:
Healthcare
Industry:
Biotechnology
Beta:
0.42
Last Dividend:
$0.90
Exchange:
NASDAQ
Country:
US
Employees:
75
IPO Date:
2020-06-16
EPS (TTM):
2.33
P/E Ratio:
21.65
Revenue (TTM):
2.38B
Total Assets:
19.62B
Total Debt:
8.95B
Cash & Equiv:
618.70M
Rev Growth (5Y):
2.3%
EPS Growth (5Y):
-1.5%
FCF Growth (5Y):
4.1%
ROCE:
8.6%
Debt/Equity:
1.38
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-02-11 | $1.46 | $1.33 | +9.8% | $622.0M | $859.0M | -27.6% |
| 2025-11-05 | $1.17 | $0.99 | +17.7% | $609.3M | $717.4M | -15.1% |
| 2025-08-06 | $1.14 | $1.03 | +10.7% | $578.7M | $673.0M | -14.0% |
| 2025-05-08 | $1.06 | $0.95 | +11.2% | $568.2M | $705.3M | -19.4% |
| 2025-02-11 | $1.15 | $0.99 | +16.2% | $594.0M | $687.1M | -13.5% |
| 2024-11-06 | $1.04 | $0.93 | +12.1% | $564.7M | $696.9M | -19.0% |
| 2024-08-08 | $0.96 | $0.96 | -0.5% | $537.3M | $627.4M | -14.4% |
| 2024-05-09 | $0.98 | $0.99 | -0.7% | $568.0M | $665.6M | -14.7% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.38B | 2.26B | 2.35B | 2.24B | 2.29B | 2.12B | 1.81B | 1.79B | 1.60B | 1.88B | 1.65B |
| Net Income | 770.95M | 858.98M | 1.13B | 42.83M | 619.73M | 975.04M | 2.35B | 1.38B | 1.21B | 565.91M | 581.43M |
| EPS | 2.33 | 1.92 | 2.54 | 0.10 | 1.49 | 2.51 | 6.63 | 3.89 | 3.42 | 0.93 | 0.96 |
| Total Assets | 19.62B | 18.22B | 16.38B | 16.81B | 17.52B | 16.02B | 12.45B | 11.37B | 11.37B | 10.48B | 10.82B |
| Total Debt | 8.95B | 7.61B | 6.14B | 7.12B | 7.10B | 5.82B | 6.24B | 6.52B | 6.80B | 5.90B | 5.99B |
| Cash & Equivalents | 618.70M | 929.03M | 477.01M | 1.71B | 1.54B | 1.01B | 246.20M | 1.92B | 1.38B | 1.67B | 1.72B |
| Operating Cash Flow | 2.49B | 2.77B | 2.99B | 2.14B | 2.02B | 2.03B | 1.67B | 1.62B | 1.42B | N/A | N/A |
| Free Cash Flow | 2.49B | 2.77B | 2.99B | 2.14B | 2.02B | 2.03B | 1.67B | 1.62B | 1.42B | N/A | N/A |
| FCF per Share | 5.76 | 6.21 | 6.68 | 4.90 | 4.86 | 5.24 | 4.71 | 4.57 | 4.00 | N/A | N/A |
| Book Value | 6.48B | 6.95B | 6.53B | 5.63B | 5.78B | 4.82B | 6.11B | 4.49B | 4.46B | 4.45B | 4.68B |
| Cash & ST Investments | 637.50M | 1.77B | 1.23B | 2.43B | 2.80B | 2.65B | 793.21M | 2.39B | 1.38B | 1.67B | 1.72B |
| ROC Equity | 0.12 | 0.12 | 0.17 | 0.01 | 0.11 | 0.20 | 0.38 | 0.31 | 0.27 | 0.13 | 0.12 |